Cargando…

Therapeutic Effects of Catechins in Less Common Neurological and Neurodegenerative Disorders

In recent years, neurological and neurodegenerative disorders research has focused on altered molecular mechanisms in search of potential pharmacological targets, e.g., imbalances in mechanisms of response to oxidative stress, inflammation, apoptosis, autophagy, proliferation, differentiation, migra...

Descripción completa

Detalles Bibliográficos
Autores principales: Sebastiani, Giorgia, Almeida-Toledano, Laura, Serra-Delgado, Mariona, Navarro-Tapia, Elisabet, Sailer, Sebastian, Valverde, Olga, Garcia-Algar, Oscar, Andreu-Fernández, Vicente
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308206/
https://www.ncbi.nlm.nih.gov/pubmed/34209677
http://dx.doi.org/10.3390/nu13072232
_version_ 1783728225670660096
author Sebastiani, Giorgia
Almeida-Toledano, Laura
Serra-Delgado, Mariona
Navarro-Tapia, Elisabet
Sailer, Sebastian
Valverde, Olga
Garcia-Algar, Oscar
Andreu-Fernández, Vicente
author_facet Sebastiani, Giorgia
Almeida-Toledano, Laura
Serra-Delgado, Mariona
Navarro-Tapia, Elisabet
Sailer, Sebastian
Valverde, Olga
Garcia-Algar, Oscar
Andreu-Fernández, Vicente
author_sort Sebastiani, Giorgia
collection PubMed
description In recent years, neurological and neurodegenerative disorders research has focused on altered molecular mechanisms in search of potential pharmacological targets, e.g., imbalances in mechanisms of response to oxidative stress, inflammation, apoptosis, autophagy, proliferation, differentiation, migration, and neuronal plasticity, which occur in less common neurological and neurodegenerative pathologies (Huntington disease, multiple sclerosis, fetal alcohol spectrum disorders, and Down syndrome). Here, we assess the effects of different catechins (particularly of epigalocatechin-3-gallate, EGCG) on these disorders, as well as their use in attenuating age-related cognitive decline in healthy individuals. Antioxidant and free radical scavenging properties of EGCG -due to their phenolic hydroxyl groups-, as well as its immunomodulatory, neuritogenic, and autophagic characteristics, makes this catechin a promising tool against neuroinflammation and microglia activation, common in these pathologies. Although EGCG promotes the inhibition of protein aggregation in experimental Huntington disease studies and improves the clinical severity in multiple sclerosis in animal models, its efficacy in humans remains controversial. EGCG may normalize DYRK1A (involved in neural plasticity) overproduction in Down syndrome, improving behavioral and neural phenotypes. In neurological pathologies caused by environmental agents, such as FASD, EGCG enhances antioxidant defense and regulates placental angiogenesis and neurodevelopmental processes. As demonstrated in animal models, catechins attenuate age-related cognitive decline, which results in improvements in long-term outcomes and working memory, reduction of hippocampal neuroinflammation, and enhancement of neuronal plasticity; however, further studies are needed. Catechins are valuable compounds for treating and preventing certain neurodegenerative and neurological diseases of genetic and environmental origin. However, the use of different doses of green tea extracts and EGCG makes it difficult to reach consistent conclusions for different populations.
format Online
Article
Text
id pubmed-8308206
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83082062021-07-25 Therapeutic Effects of Catechins in Less Common Neurological and Neurodegenerative Disorders Sebastiani, Giorgia Almeida-Toledano, Laura Serra-Delgado, Mariona Navarro-Tapia, Elisabet Sailer, Sebastian Valverde, Olga Garcia-Algar, Oscar Andreu-Fernández, Vicente Nutrients Review In recent years, neurological and neurodegenerative disorders research has focused on altered molecular mechanisms in search of potential pharmacological targets, e.g., imbalances in mechanisms of response to oxidative stress, inflammation, apoptosis, autophagy, proliferation, differentiation, migration, and neuronal plasticity, which occur in less common neurological and neurodegenerative pathologies (Huntington disease, multiple sclerosis, fetal alcohol spectrum disorders, and Down syndrome). Here, we assess the effects of different catechins (particularly of epigalocatechin-3-gallate, EGCG) on these disorders, as well as their use in attenuating age-related cognitive decline in healthy individuals. Antioxidant and free radical scavenging properties of EGCG -due to their phenolic hydroxyl groups-, as well as its immunomodulatory, neuritogenic, and autophagic characteristics, makes this catechin a promising tool against neuroinflammation and microglia activation, common in these pathologies. Although EGCG promotes the inhibition of protein aggregation in experimental Huntington disease studies and improves the clinical severity in multiple sclerosis in animal models, its efficacy in humans remains controversial. EGCG may normalize DYRK1A (involved in neural plasticity) overproduction in Down syndrome, improving behavioral and neural phenotypes. In neurological pathologies caused by environmental agents, such as FASD, EGCG enhances antioxidant defense and regulates placental angiogenesis and neurodevelopmental processes. As demonstrated in animal models, catechins attenuate age-related cognitive decline, which results in improvements in long-term outcomes and working memory, reduction of hippocampal neuroinflammation, and enhancement of neuronal plasticity; however, further studies are needed. Catechins are valuable compounds for treating and preventing certain neurodegenerative and neurological diseases of genetic and environmental origin. However, the use of different doses of green tea extracts and EGCG makes it difficult to reach consistent conclusions for different populations. MDPI 2021-06-29 /pmc/articles/PMC8308206/ /pubmed/34209677 http://dx.doi.org/10.3390/nu13072232 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Sebastiani, Giorgia
Almeida-Toledano, Laura
Serra-Delgado, Mariona
Navarro-Tapia, Elisabet
Sailer, Sebastian
Valverde, Olga
Garcia-Algar, Oscar
Andreu-Fernández, Vicente
Therapeutic Effects of Catechins in Less Common Neurological and Neurodegenerative Disorders
title Therapeutic Effects of Catechins in Less Common Neurological and Neurodegenerative Disorders
title_full Therapeutic Effects of Catechins in Less Common Neurological and Neurodegenerative Disorders
title_fullStr Therapeutic Effects of Catechins in Less Common Neurological and Neurodegenerative Disorders
title_full_unstemmed Therapeutic Effects of Catechins in Less Common Neurological and Neurodegenerative Disorders
title_short Therapeutic Effects of Catechins in Less Common Neurological and Neurodegenerative Disorders
title_sort therapeutic effects of catechins in less common neurological and neurodegenerative disorders
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308206/
https://www.ncbi.nlm.nih.gov/pubmed/34209677
http://dx.doi.org/10.3390/nu13072232
work_keys_str_mv AT sebastianigiorgia therapeuticeffectsofcatechinsinlesscommonneurologicalandneurodegenerativedisorders
AT almeidatoledanolaura therapeuticeffectsofcatechinsinlesscommonneurologicalandneurodegenerativedisorders
AT serradelgadomariona therapeuticeffectsofcatechinsinlesscommonneurologicalandneurodegenerativedisorders
AT navarrotapiaelisabet therapeuticeffectsofcatechinsinlesscommonneurologicalandneurodegenerativedisorders
AT sailersebastian therapeuticeffectsofcatechinsinlesscommonneurologicalandneurodegenerativedisorders
AT valverdeolga therapeuticeffectsofcatechinsinlesscommonneurologicalandneurodegenerativedisorders
AT garciaalgaroscar therapeuticeffectsofcatechinsinlesscommonneurologicalandneurodegenerativedisorders
AT andreufernandezvicente therapeuticeffectsofcatechinsinlesscommonneurologicalandneurodegenerativedisorders